Is ‘Obsession' Technically A Blockbuster? Lawyers For Paramount, State AGs Spar At Court Hearing On WBD Merger

This is less a headline-driven media event than a duration shock for WBD. When antitrust review becomes public theater, the equity tends to trade on calendar drift: every month of uncertainty keeps the multiple pinned because investors cannot fully underwrite either synergy capture or standalone deleveraging. That dynamic usually benefits better-capitalized peers with cleaner strategic narratives — especially NFLX and DIS — which can keep investing aggressively while WBD remains stuck in procedural limbo.

The real economic damage is second-order. A delayed or contested process means WBD has to carry integration expectations without the balance-sheet relief that would justify them, so the market will likely pressure 2025-26 FCF assumptions more than near-term revenue. If the legal path stretches into multiple quarters, the overhang can also dampen employee retention and content negotiations, because counterparties discount a company whose ownership structure may change again.

Contrarianly, the market may be over-fixated on binary close/no-close and underpricing the worse middle state: prolonged litigation with no strategic action. That outcome is often the most value-destructive because it delays capital allocation decisions and keeps the equity in a no-man’s-land between turnaround and takeout optionality. For WBD, the key falsifier is a clear court schedule or ruling that meaningfully shortens the path; absent that, the stock should trade with a persistent legal discount rather than re-rate on hope.